Introduction
We perform a comprehensive evaluation of all treatment possibilities by detecting variants in 64 target genes associated with myeloid hematologic malignancies using blood or bone marrow samples. This ultimately helps the patient find the most suitable treatment options, guided by matched targeted therapy and chemotherapy recommendations."
Features / strengths
1. International Standards, Local Services
2. National Laboratory Quality Certification
3. Using NGS Leading Technology
4. Fast and Accurate Report Issuance
5. Complete Clinical Trial Basis
Specification in detail
